Center for Strategic Science Initiatives
Office of the Director
National Cancer Institute
Emily J. Greenspan is a Program Director in the Center for Strategic Scientific Initiatives (CSSI), Office of the Director, National Cancer Institute. In her role, she directs and assists in the planning, implementation and management of CSSI programs and resources, including the Office of Cancer Clinical Proteomics Research (OCCPR), the Office of Cancer Nanotechnology Research (OCNR) and the Innovative Molecular Analysis Technologies (IMAT) Program, by encouraging interdisciplinary collaborations of investigators and researchers within the CSSI network. Dr. Greenspan serves as the Program Director for the NCI’s Provocative Questions Initiative, and through this role has led a trans-NCI Program Team that oversees and manages programmatic and funding aspects of the Initiative. She also serves as the government sponsor on multiple R&D contracts with the National Academy of Sciences and Leidos Biomedical Research to support innovation in biomedical research and engineering.
Prior to joining the CSSI, Dr. Greenspan was a postdoctoral fellow in the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, DC where her research focused on cancer chemoprevention strategies using naturally occurring compounds. Specifically, she investigated the effects of green tea on modulating biomarkers of oral cancer risk and the mechanisms of lung tumor inhibition by isothiocyanates, compounds found in cruciferous vegetables. At Georgetown, she also co-directed a career development program aimed at educating and mentoring young scientists.
Dr. Greenspan received her Ph.D. in Biomedical Sciences from the University of Connecticut Health Center in 2010. Her doctoral work focused on elucidating the molecular alterations in human pre-neoplastic colon lesions and defining mechanisms of non-steroidal anti-inflammatory drug (NSAID) chemoprevention of colorectal cancer. She has co-authored several research publications related to overcoming NSAID resistance and the interplay between Wnt signaling and arachidonic acid metabolism. Dr. Greenspan is interested in promoting cancer prevention and translational science by leading research development efforts and enabling strategic partnerships.